Cargando…
Nimodipine Reappraised: An Old Drug with a Future
Nimodipine is a dihydropyridine calcium channel antagonist that blocks the flux of extracellular calcium through L-type, voltage-gated calcium channels. While nimodipine is FDA-approved for the prevention and treatment of neurological deficits in patients with aneurysmal subarachnoid hemorrhage (aSA...
Autores principales: | Carlson, Andrew P., Hänggi, Daniel, Macdonald, Robert L., Shuttleworth, Claude W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327937/ https://www.ncbi.nlm.nih.gov/pubmed/31560289 http://dx.doi.org/10.2174/1570159X17666190927113021 |
Ejemplares similares
-
An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective
por: Athira, Kaipuzha Venu, et al.
Publicado: (2020) -
The Kinetic Component in Drug Discovery: Using the Most Basic Pharmacological Concepts to Advance in Selecting Drugs to Combat CNS Diseases
por: Franco, Rafael, et al.
Publicado: (2020) -
Diverse antiepileptic drugs increase the ratio of background synaptic inhibition to excitation and decrease neuronal excitability in neurones of the rat entorhinal cortex in vitro
por: Greenhill, S.D., et al.
Publicado: (2010) -
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis
por: Svensson, Kjell A., et al.
Publicado: (2017) -
Noncompetitive Inhibition of 5-HT(3) Receptors by Citral, Linalool, and Eucalyptol Revealed by Nonlinear Mixed-Effects Modeling
por: Jarvis, Gavin E., et al.
Publicado: (2016)